BioMarin Pharmaceutical, Inc. (BMRN)
65.04
-1.66
(-2.50%)
USD |
NASDAQ |
Aug 24, 16:00
65.04
0.00 (0.00%)
After-Hours: 20:00
BioMarin Pharmaceutical Price to Book Value : 1.991 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 2.042 |
| August 20, 2026 | 2.072 |
| August 19, 2026 | 2.122 |
| August 18, 2026 | 2.051 |
| August 17, 2026 | 2.040 |
| August 14, 2026 | 2.062 |
| August 13, 2026 | 2.098 |
| August 12, 2026 | 2.150 |
| August 11, 2026 | 2.129 |
| August 10, 2026 | 2.109 |
| August 07, 2026 | 1.954 |
| August 06, 2026 | 1.882 |
| August 05, 2026 | 1.834 |
| August 04, 2026 | 1.859 |
| August 03, 2026 | 1.837 |
| July 31, 2026 | 1.838 |
| July 30, 2026 | 1.855 |
| July 29, 2026 | 1.879 |
| July 28, 2026 | 1.900 |
| July 27, 2026 | 1.845 |
| July 24, 2026 | 1.816 |
| July 23, 2026 | 1.802 |
| July 22, 2026 | 1.788 |
| July 21, 2026 | 1.813 |
| July 20, 2026 | 1.810 |
| Date | Value |
|---|---|
| July 17, 2026 | 1.824 |
| July 16, 2026 | 1.837 |
| July 15, 2026 | 1.805 |
| July 14, 2026 | 1.795 |
| July 13, 2026 | 1.812 |
| July 10, 2026 | 1.810 |
| July 09, 2026 | 1.836 |
| July 08, 2026 | 1.829 |
| July 07, 2026 | 1.848 |
| July 06, 2026 | 1.800 |
| July 02, 2026 | 1.806 |
| July 01, 2026 | 1.770 |
| June 30, 2026 | 1.752 |
| June 29, 2026 | 1.794 |
| June 26, 2026 | 1.836 |
| June 25, 2026 | 1.784 |
| June 24, 2026 | 1.784 |
| June 23, 2026 | 1.758 |
| June 22, 2026 | 1.739 |
| June 18, 2026 | 1.702 |
| June 17, 2026 | 1.712 |
| June 16, 2026 | 1.715 |
| June 15, 2026 | 1.731 |
| June 12, 2026 | 1.741 |
| June 11, 2026 | 1.728 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Incyte Corp. | 4.054 |
| Alnylam Pharmaceuticals, Inc. | 23.31 |
| Vertex Pharmaceuticals, Inc. | 6.854 |
| Ionis Pharmaceuticals, Inc. | 23.36 |
| Regeneron Pharmaceuticals, Inc. | 2.702 |
Price to Book Value Related Metrics
| PE Ratio | 175.34 |
| PS Ratio | 3.652 |
| Price to Free Cash Flow | 17.41 |
| Price | 65.04 |
| Earnings Yield | 0.57% |
| Market Cap | 12.59B |
| Operating PE Ratio | 19.74 |
| Normalized PE Ratio | 33.01 |